Answers are grounded in this paper and cite their sources.
Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec. This review assesses palopegteriparatide (Yorvipath) 168 mcg/0.56 mL, 294 mcg/0.98 mL, and 420 mcg/1.4 mL solution for subcutaneous injection. Indication: For the treatment of chronic hypoparathyroidism in adults.
No takes yet. Share an insight, caveat, or question.
CDA-AMC (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: